The state of Pennsylvania currently has 4 active clinical trials seeking participants for Hereditary Angioedema (HAE) research studies. These trials are conducted in various cities, including Philadelphia, Pittsburgh, Hershey and Allentown.
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).
Gender:
All
Ages:
12 years and above
Trial Updated:
06/14/2024
Locations: Ionis Investigative Site, Hershey, Pennsylvania
Conditions: Hereditary Angioedema
A Study of STAR-0215 in Participants With Hereditary Angioedema
Recruiting
The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Hereditary Angioedema
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Recruiting
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/06/2024
Locations: KalVista Investigative Site, Hershey, Pennsylvania
Conditions: Hereditary Angioedema
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
Recruiting
This is a multicenter pharmacokinetic (PK) subtrial to investigate the PK profile of KVD900 in adolescent patients 12 to 17 years of age with Hereditary Angioedema (HAE) type I or II.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
03/06/2024
Locations: Kalvista Investigative Site, Hershey, Pennsylvania
Conditions: Hereditary Angioedema